

**Colin J. Dunn, Ph.D.**

**CJD PHARMACOLOGY CONSULTANTS, LLC**

**- RESUME (1998-Present) -**

**CONTACT**

Richland, MI (June-September: Phone: 269 629 4103)  
Mazatlan, Mexico (October-May: Phone 01152-669 982 6279)  
e-mail: [cjdpharma@gmail.com](mailto:cjdpharma@gmail.com)

**EDUCATION**

Ph.D. London University  
Thesis: Experimental Pathology: Some Aspects of the  
Inflammatory Reaction in the Young and Newborn Rat.

B.Sc. University of Southampton  
Physiology and Biochemistry (Hons)

**LANGUAGES** French, Spanish

**CAREER HISTORY (1978-Present)**

Medical/Science Writer and Consultant, **CJD PHARMACOLOGY CONSULTANTS, LLC.**

Senior Research Scientist, Dept. Pharmacology, **PHARMACIA & UPJOHN, KALAMAZOO, MI**

Research Scientist, Dept. Hypersensitivity Diseases Research, **PHARMACIA & UPJOHN, KALAMAZOO, MI**

Director of Inflammation Research and Development, **BAYER, COLOGNE, W. GERMANY**

Associate Director, Dept. Pharmacologie Generale/Douleur et Inflammation, **SYNTHELABO, BAGNEUX, FRANCE**

Chef de Laboratoire, Dept. Pharmacologie Generale/Douleur et Inflammation, **SYNTHELABO, BAGNEUX, FRANCE**

Pre-clinical lecturer, Dept. Experimental Pathology and Rheumatology, **ST. BARTHOLOMEWS HOSPITAL, LONDON, ENGLAND**

INSERM Postdoctoral Research Fellow, Dept. Pharmacologie, **HÔPITAL COCHIN, PARIS, FRANCE**

**MEMBERSHIP IN PROFESSIONAL SOCIETIES**

The Royal Society of Medicine. London, UK.

Inflammation Research Association, USA.

The New York Academy of Sciences, USA

American Association for the Advancement of Science.

American Medical Writers Association.

## **MEDICAL WRITING/COMMUNICATIONS (1998 – present)**

### **Osteoporosis/Bone Disease**

- 1998. Review: Osteoporosis, and Treatment Options. **PROJECT HOUSE, NJ**
- 1999. Prepared, annotated and edited slide kit: Bisphosphonate Treatment of Paget's Disease. **PROJECT HOUSE, NJ**
- 1999. Prepared, annotated and edited slide kit: Bisphosphonate Treatment of Glucocorticoid-induced Osteoporosis. **PROJECT HOUSE, NJ**
- 1999. Evaluated preclinical data and prepared an IND for an osteoporosis therapeutic agent for Dr. Denis Schrier, **PARKE-DAVIS, ANN ARBOR, MI**
- 2000. Review: Emerging Therapies for Osteoporosis. Basic Pharmacology, Disease Pathogenesis Preclinical /Clinical Research, and Marketing. Study # 23, November 2000. **DECISION RESOURCES, BOSTON, MA**
- 2001. Primary data manuscript: Therapy for Osteoporosis. (CONFIDENTIAL) **PHASE FIVE COMMUNICATIONS, NY**
- 2001-2002. CME Program: Osteoporosis. **INTERNATIONAL MEETINGS AND SCIENCE, CT**
- 2002-2003. Attended osteoporosis CME meetings; discussed and summarized speaker presentations. **INTERNATIONAL MEETINGS AND SCIENCE, CT**
- 2004. Primary data manuscripts: Novel Therapies for Osteoporosis. **APOTHECOM, PA**
- 2004. Review: PTH and CPTH Fragments – Relevance to Bone Biology and Disease. **APOTHECOM, PA**
- 2005. Posters: Epidemiology of Osteoporosis. **PPS INTERNATIONAL, STAMFORD, CT**
- 2005. Consulting: Selective Estrogen Receptor Modulators for Osteoporosis Therapy. **PPS INTERNATIONAL, STAMFORD, CT**

### **Arthritis/Dermatology/IBD/Allergy/Cytokines/Inflammation/COX-2**

- 1998. Overview/editorial: Mechanisms of Action of Sulfasalazine in RA therapy. **SDR GLOBAL, MI and MPE, NJ**
- 1999-2000. Review: Emerging Matrix Metalloproteinase Inhibitors: Basic Pharmacology, Pathogenesis of Inflammatory Diseases and Cancer, Preclinical /Clinical Research, and Marketing. Study # 19, June 2000. **DECISION RESOURCES, BOSTON, MA**
- 2000. Review: The Role of Cytokines in the Pathogenesis of Arthritis, Asthma, Inflammatory Bowel Disease, and Transplantation. Study # 32, December 1, 2000. **DECISION RESOURCES, BOSTON, MA**
- 2000. Review: Preclinical Development of Cytokine-Based Therapies for Inflammatory Diseases. Study # 32, December 1, 2000. **DECISION RESOURCES, BOSTON, MA**
- 2001. Review: Tumor Necrosis Factor-Alpha: A Mediator of Physiological and Pathological Control Mechanisms. **DECISION RESOURCES, BOSTON, MA**
- 2001. Review: The Role of TNF-alpha in the Pathogenesis of Arthritis, Inflammatory Bowel Disease, Congestive Heart Failure, Sepsis, and Septic Shock. **DECISION RESOURCES, BOSTON, MA**
- 2001. Juvenile Arthritis – An Overview. **PROHEALTH Inc., CA**  
<http://www.arthritissupport.com/library/showarticle.cfm/id/298/e/1>
- 2002-2003. CME Program: Inflammatory Disease and Novel Anti-Inflammatory Agents. **INTERNATIONAL MEETINGS AND SCIENCE, CT**

- 2006. Review: Allergic Conjunctivitis: Future Trends in the Management of Allergic Conjunctivitis. **HEALTH SCIENCE COMMUNICATIONS, NY**
- 2008-2010. Review Assessment of biological therapies for rheumatoid arthritis. **APOTHECOM, PA**
- 2008-2010. Abstracts and posters on clinical trials of anti-IL-6 therapy in RA. **APOTHECOM, PA**
- 2008-2010. Reviews: Novel biological therapies for rheumatoid arthritis. **APOTHECOM, PA**
- 2011. Review: Rosacea Epidemiology, Pathogenesis, Diagnosis, and Topical Treatment. **EVINCE, CT**
- 2012. Review for Nurse Practitioners and Physician Assistant education on rosacea therapy "It's not acne". **EVINCE, CT**
- 2012: Review: Optimal Management of Papulopustular Rosacea: Rationale for Combination Therapy. **EVINCE, CT**

### **Urogenital**

- 2000. Review: Expert Opinion on Therapy for Urinary Incontinence. **APOTHECOM, PA**
- 2000-2001. Review: Benign Prostatic Hyperplasia: Basic Pharmacology, Disease Pathogenesis Preclinical /Clinical Research, and Marketing. Study # 26, April 1, 2001. **DECISION RESOURCES, BOSTON, MA**
- 2001. Review: Pathogenesis, Epidemiology, and Treatment of Urinary Incontinence – Outlook for Urinary Incontinence Therapies through 2005. **DECISION RESOURCES, BOSTON, MA**
- 2002. Review: Outlook for Benign Prostatic Hyperplasia Therapeutics: Therapy, Markets and Emerging Technologies. **DECISION RESOURCES, BOSTON, MA**
- 2002-2004. Monograph and Reviews on Urinary Incontinence, Disease Assessment, and Therapy. **INTERNATIONAL MEETINGS AND SCIENCE, CT**
- 2004-2005. Slide kits: The Surgical Application of Bulking agents for Treatment of Urinary Incontinence. **INTERNATIONAL MEETINGS AND SCIENCE, CT**

### **Gastroenterology/ IBD/GERD/PPIs**

- 2002. Developed historical outline for The Discovery and Development of *Helicobacter Pylori* and Proton Pump Inhibitors (PPIs), 1930-2002. **INTERNATIONAL MEETINGS AND SCIENCE, CT**
- 2003. Prepared posters for proton pump inhibitors. **INTERNATIONAL MEETINGS AND SCIENCE, CT**
- 2004. Review: Gastroesophageal reflux disease (GERD): symptoms and treatment. **INTERNATIONAL MEETINGS AND SCIENCE, CT**
- 2004-2005. Primary data manuscripts: Comparative Efficacy of Proton Pump Inhibitors in Gastroesophageal Reflux Disease (GERD). **INTERNATIONAL MEETINGS AND SCIENCE, CT**
- 2005. Inflammatory bowel disease: Comparative Review of Current Pharmacotherapies. **HEALTH SCIENCE COMMUNICATIONS, NY**

### **Drug Metabolism/Resistance/Interactions**

- 2000. Review: Expert Opinion on Multi-Drug Resistance P-Glycoprotein Transport and Drug-Drug Interactions. **APOTHECOM, PA**

- 2000. Edited and converted methodology report for publication: Drug/Metabolite Analysis using Atmospheric Pressure Chemical Ionization (APCI) Liquid Chromatographic/Tandem Mass Spectrometry (LC/MS/MS). **APOTHECOM, PA**
- 2001. Composed poster for presentation: Drug-Human Histamine H<sub>1</sub> Receptor Interactions. **APOTHECOM, PA**

#### **Cancer (focus on Multiple Myeloma)**

- 2001. Attended scientific meeting on: "VIIIth International Myeloma Workshop", Banff, Canada, May 4-8. **INTERNATIONAL MEETINGS AND SCIENCE, CT**
- 2001. Composed Meeting Report on "VIIIth International Myeloma Workshop", Banff, Canada, May 4-8. **INTERNATIONAL MEETINGS AND SCIENCE, CT**
- 2001. Review (devised from round table discussion): Cellular-Molecular Mechanisms and Current Treatment Strategies in Multiple Myeloma. **GREY HEALTHCARE WEST, CA**
- 2002. Review: Unmet Needs in Multiple Myeloma – Emerging Novel Therapies. **DECISION RESOURCES, BOSTON, MA**

#### **Nephrology**

- 2001. Composed report for American Society of Nephrology Meeting: dialysis and calcimimetics. **INTERNATIONAL MEETINGS AND SCIENCE, CT**
- 2002. Composed speaker notes for slide presentation using speaker's transcripts on "The Effects of Aldosterone on the Cardiovascular System and other Organs". **APOTHECOM, PA**
- 2002. Attended American Society of Nephrology Meeting. **INTERNATIONAL MEETINGS AND SCIENCE, CT**
- 2002. Composed American Society of Nephrology Meeting Report; dialysis and calcimimetics. **INTERNATIONAL MEETINGS AND SCIENCE, CT**

#### **CNS/Pain**

- 2001. Composed a slide kit, speaker notes and abstract. The CNS Side Effects of Anticholinergic Drugs. **APOTHECOM, PA**
- 2002-2004. Review: Major Depressive Disorder and Novel Antidepressant Therapy. **INTERNATIONAL MEETINGS AND SCIENCE, CT**
- 2003-2004. Review: Major Depressive Disorder and Novel Antidepressant Therapy – An Update. **INTERNATIONAL MEETINGS AND SCIENCE, CT**
- 2006. Review: Pharmacotherapy of Central Pain. **HEALTH SCIENCE COMMUNICATIONS, NY**
- 2007. Composed slide kit, speaker notes: Disadvantages of Opioid Therapy in Chronic Pain. **HEALTH SCIENCE COMMUNICATIONS, NY**
- 2007. Review: Treatment Strategies for Chronic Pain. **HEALTH SCIENCE COMMUNICATIONS, NY**
- 2007. Composed slides for opioid side effects. **HEALTH SCIENCE COMMUNICATIONS, NY**
- 2007. Composed slides and slide notes for mechanisms of Acute and Chronic Pain. **HEALTH SCIENCE COMMUNICATIONS, NY**
- 2007. Composed slides and slide notes for treatment of chronic pain. **HEALTH SCIENCE COMMUNICATIONS, NY**
- 2007. Critical review on Management of Chronic Pain. **HEALTH SCIENCE COMMUNICATIONS, NY**

- 2007-2008. Slide notes on: Treatment of the neuropathic patient: a guide for nurses. **APOTHECOM, PA**
- 2009-2010. Review: A physician's guide to the causes and consequences of acute pain. **HEALTH SCIENCE COMMUNICATIONS, NY**
- 2010-2012. Chronic Pain: Reducing Costs through Early Implementation of Adherence Testing and Recognition of Opioid Misuse. **EVINCE, CT**
- 2010-2012. A Critical Assessment of Opioid Treatment Adherence Using Urine Drug Testing in Chronic Pain Management. **EVINCE, CT**

#### **Cardiovascular/Lipids/Stents**

- 2002-2004. CME Program: Lipid Metabolism and Novel Lipid-Lowering Therapeutic Strategies. **INTERNATIONAL MEETINGS AND SCIENCE, CT**
- 2001. Review: Critical analysis of current and emerging therapeutic agents for congestive heart failure, thrombosis, myocardial infarction, angina, hyperlipidemia, and osteoporosis. **PHARMACIA, NEW JERSEY, NJ**
- 2006. Composed slides and speaker notes for Bare Metal- and Drug-Eluting stents. **HEALTH SCIENCE COMMUNICATIONS, NY**
- 2007. Composed slides for cardiovascular disease therapy. **HEALTH SCIENCE COMMUNICATIONS, NY**
- 2011. Review: Clinical pharmacokinetics of edoxaban and M4 metabolite – assay validation in clinical samples. **EVINCE, CT**

#### **Ophthalmology**

- 2001. Primary data manuscript: Viscocanalostomy: An Alternative Surgical Approach to Glaucoma. **PHARMACIA, NEW JERSEY, NJ**
- 2006. Prepared supplement for allergic conjunctivitis. **TSG, NY**
- 2006. Review: Current Trends in Diagnosis and Treatment of Ocular Rosacea. **SCIENTIFIC FRONTIERS, PA**

#### **Infectious Diseases**

- 2000. Devised graphic schematic presentation for anti-HIV therapeutic mechanisms (using powerpoint). **APOTHECOM, PA**
- 2008-2010. Advances in the Prevention of Invasive Meningococcal Serogroup B Disease. **INTERNATIONAL MEETINGS AND SCIENCE, CT**
- 2010-2-11. Review of carrier proteins used in pneumococcal and meningococcal vaccines. **INTERNATIONAL MEETINGS AND SCIENCE, CT**

#### **Clinical Study Reports**

- 2001. Clinical study reports – Arthritis and Cardiovascular. (CONFIDENTIAL) **SEARLE DIVISION OF PHARMACIA, IL**
- 2002. Clinical study reports – Cardiovascular. (CONFIDENTIAL) **SEARLE DIVISION OF PHARMACIA, IL**

#### **Miscellaneous**

- 1999. Prepared Strategic Research Assessment of competitor therapeutics for Diabetes, Obesity, Growth Hormone and Osteoporosis using online databases (IDdb, R&D Focus, R&D Insight) for Dr. Duncan PTaylor, **PHARMACIA & UPJOHN, MI**

- 200-2001. Composed Physician Response Letters, updating pharmacotherapy for cardiovascular diseases, diabetes, infection, and depression. **LYONS, LAVEY, NICKEL AND SWIFT, NEW YORK, NY**
- 2002. Primary data manuscript: Efficacy and Safety of Antifungal Therapy. (CONFIDENTIAL) **APOTHECOM, PA**
- 2004. Primary data manuscript: Gene Expression Profiling for Drug Development. **APOTHECOM, PA**

**CONSULTING (1998-Present)**

October, 1998: Experimental protocols for testing therapeutics in models of asthma, **REGENERON, NJ.**

1998-Present: Consulting/histopathology for arthritis and transplantation programs, **ABBOTT/BASF BIORESEARCH, Worcester, MA.**

1998-2000: Consulting/histopathology for antithrombotic therapy in the rat, **ALZA CORP., CA.**

1999-2000: Consulting/histopathology for osteochondral defect repair, **OSTEOBIOLOGICS, Inc, TX.**

1999-2000: Consulting/histopathology for rheumatoid arthritis, osteoarthritis, and osteoporosis. **PARKE-DAVIS, ANN ARBOR, MI.**

1999-2007: Experimental approaches to asthma therapy, **GENETICS INSTITUTE, BOSTON, MA**

2000-Present: Scientific Consultant for Decision Resources, **Boston, MA and London, UK**

2001-Present: Scientific Consultant for International Meetings & Science, **Stamford, CT**

2005-Present: Scientific Consultant for PPS International, **Stamford, CT**

2010-Present: Scientific Consultant for Evince, **Norwalk, CT**



**MAJOR CLIENTS**

APOTHECOM, PA  
ABBOTT/BASF BIORESEARCH, MA  
COMPLETE HEALTHCARE COMMUNICATIONS, INC., NY  
DECISION RESOURCES, MA  
EVINCE, CT  
GENETICS INSTITUTE, MA  
GREY HEALTHCARE WEST, CA  
INTERNATIONAL MEETINGS & SCIENCE, CT  
LYONS, LAVEY, NICKEL AND SWIFT, NY  
MPE COMMUNICATIONS, NJ  
PHARMACIA & UPJOHN, MI  
PHARMACIA CORPORATION, MI & IL  
PHASE FIVE COMMUNICATIONS, NY  
PFIZER, MI  
PROJECT HOUSE, NJ  
REGENERON, NJ  
SDR GLOBAL COMMUNICATIONS, MI  
WARNER LAMBERT/ PARKE-DAVIS, MI